[go: up one dir, main page]

LeBlanc et al., 1985 - Google Patents

Timolol: long-term Canadian multicentre study

LeBlanc et al., 1985

Document ID
5971915083037637481
Author
LeBlanc R
Saheb N
Krip G
Publication year
Publication venue
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

External Links

Snippet

This paper reports a 200-week-long study of the efficacy of timolol maleate ophthalmic preparations. At centres across Canada 117 patients were studied according to a rigid protocol. Timolol maleate was shown to be an effective antiglaucomatous drug, maintaining …
Continue reading at pubmed.ncbi.nlm.nih.gov (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Method or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Method or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body

Similar Documents

Publication Publication Date Title
AU2002319606B2 (en) Ophthalmic drug delivery device
Robin Short-term effects of unilateral 1% apraclonidine therapy
Steinert et al. Long-term drift and continued efficacy after multiyear timolol therapy
WO2003009774A3 (en) Ophthalmic drug delivery device
KR20020059630A (en) Drug delivery device
JPH10507743A (en) Methods and means for drug administration
Smith The Lang lecture 1986. The enigma of primary open-angle glaucoma
US6534082B1 (en) Method of treating disorders of the eye
Blumenkranz et al. Fluid-gas exchange and photocoagulation after vitrectomy: indications, technique, and results
EP0979652B1 (en) Remedial composition for intraocular hypertension or glaucoma
LeBlanc et al. Timolol: long-term Canadian multicentre study
EP0403360A3 (en) Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders
WO1989002270A1 (en) Method of lowering intraocular (eye) pressure
CA2124011A1 (en) Microdelivery device and method for enhanced drug administration to the eye
Pascoe et al. Arterial hypertension associated with topical ocular use of phenylephrine in dogs
Oosterhuis Guanethidine (Ismelin) in ophthalmology: II. Clinical application in glaucoma
Vallat Surgical treatment of retinal detachment from macular hole
AU2129200A (en) Use of nerve growth factor for therapy of intraocular tissue pathologies
US4188394A (en) Ophthalmic composition and method of use
West The Use of Certain Cannabis Derivatives
CA2005754A1 (en) Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
Blondeau et al. Cardiovascular effects of epinephrine and dipivefrin in patients using timolol: a single-dose study
Goldberg Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 2001; 10: 414-22
Goethals et al. Long-Term Treatment of Chronic Open Angle Glaucoma with Topical Pindolol 1%
江樵熹 Ocular drug delivery systems of antiglaucoma agents